# Cellestia Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellestia-biotech

- Industry: Pharmaceuticals
- Headquarters: Basel, Switzerland
- Website: www.cellestia.com
- Total disclosed funding: $46M
- Latest round: Series B (Dec 17, 2019)
- Investors on record: 4

## About

Cellestia Biotech AG is a biotechnology company focused on developing innovative therapies for autoimmune diseases and multi-drug resistant cancers, striving to address significant unmet medical needs.Founded in 2014, Cellestia Biotech AG is based in Basel, Switzerland. The company specializes in creating therapeutic solutions targeting drug-resistant conditions. Raj Lehal, the founder and CEO, has previously founded other companies. The most recent funding round, Series B, raised CHF 20.000 mn from investors including Function Capital, PPF Group, and Partners Investment, culminating in a total amount raised of CHF 20.000 mn. The company has completed a total of 6 deals, with the latest deal dated August 17, 2021.Cellestia Biotech AG specializes in the development of innovative therapeutic solutions targeting autoimmune diseases and multi-drug resistant cancers. Their core product offerings include CB-103, a pioneering transcriptional Notch inhibitor, which is currently undergoing clinical trials for conditions like breast cancer and hematological malignancies. The company primarily serves healthcare providers and research institutions across Europe and North America, targeting hospitals, specialty clinics, and pharmaceutical partners involved in advanced cancer care.Cellestia Biotech AG's revenue model is based on strategic partnerships within the biopharmaceutical industry, engaging in collaborative agreements with research institutions, pharmaceutical companies, and clinical trial networks. Revenue is generated through milestone payments and royalties upon successful commercialization of therapies, particularly for flagship products like CB-103. The pricing structure for their products is determined based on partnership agreements, emphasizing B2B transactions that focus on long-term collaborations to advance medical innovation.Cellestia Biotech AG plans to utilize its recent funding from the August 2021 venture round to support the development of new therapies tailored to oncology patients lacking treatment options. The company is actively designing upcoming therapies that will target previously undrugged conditions. Additionally, Cellestia aims to expand its market reach into new geographic regions, focusing on European and North American markets by 2023.

## Funding rounds

- Series B, Dec 17, 2019, $20M — Partners Investment, Function Capital, PPF Group
- Series A, Dec 19, 2018, $20M — Emerging Technology Partners, Function Capital, PPF Group
- Seed, Jan 26, 2017, $5.2M — PPF Group

## Investors

- PPF Group (https://capitalatlas.ai/funds/ppf-group) — Seed, Series A, Series B
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series A
- Function Capital (https://capitalatlas.ai/funds/function-capital) — Series A, Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B